http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26594894.html si-local-file:///var/storage/secattach/20260603/26594894.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26594894.html Wed, 03 Jun 2026 06:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26594894.html si-local-file:///var/storage/secattach/20260603/26594894.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26594894.html Wed, 03 Jun 2026 06:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jan+20/26589841.html si-local-file:///var/storage/secattach/20260602/26589841.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jan+20/26589841.html Tue, 02 Jun 2026 11:39:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jan+20/26589841.html si-local-file:///var/storage/secattach/20260602/26589841.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jan+20/26589841.html Tue, 02 Jun 2026 11:39:00 -0400 DRUG O.53098441 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Bright+Minds+Biosciences+Inc.+%28DRUG%29/26587097.html <p>H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $145.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).</p><p>The analyst commented: "BMB-101 registrational development continues to anchor our investment thesis, which we believe is now on a de-risked path following positive BREAKTHROUGH data in Absence seizures and developmental and epileptic encephalopathies (DEEs). The positive top-line data from the open-label Phase 2 BREAKTHROUGH trial in drug-resistant epilepsy reported on January 6 were the key update for the quarter, where BMB-101 demonstrated a 73.1% median reduction in Absence seizures and a 63.3% median reduction in major motor seizures in DEEs (link http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Bright+Minds+Biosciences+Inc.+%28DRUG%29/26587097.html Tue, 02 Jun 2026 06:57:33 -0400 DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+May+26/26560517.html si-local-file:///var/storage/secattach/20260528/26560517.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+May+26/26560517.html Thu, 28 May 2026 06:03:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+May+26/26560517.html si-local-file:///var/storage/secattach/20260528/26560517.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+May+26/26560517.html Thu, 28 May 2026 06:03:00 -0400 DRUG O.53098441 http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html <p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;vertical-align: middle; text-align: left; padding-left: 30.0px; text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>DATE:</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ; vertical-align: middle; vertical-align: http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Jefferies+Global+Healthcare+Conference/26551849.html Tue, 26 May 2026 19:18:00 -0400 DRUG DRUG O.53098441 http://www.streetinsider.com/Analyst+PT+Change/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24220+at+Piper+Sandler/26524539.html <p>Piper Sandler analyst Yasmeen Rahimi raised the price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG) to $220.00 (from $190.00) while maintaining an Overweight rating.</p><p>The analyst commented: "We caught up with DRUG following earnings, where mgmt reflected confidence in the progress made across programs this past quarter. Starting with PWS, DRUG shared that PoC Ph2a NOVA has kicked-off recruitment with 2 sites activated (another one to be soon) where recent competitor data may provide tailwinds to support patient recruitment. Regarding BMB-101 development in absence epilepsy and DEE, recognize that regulatory discussions are ongoing where DRUG is preparing for a pre-IND http://www.streetinsider.com/Analyst+PT+Change/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24220+at+Piper+Sandler/26524539.html Wed, 20 May 2026 06:52:52 -0400 DRUG http://www.streetinsider.com/Analyst+Comments/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24220+at+Piper+Sandler/26524539.html <p>Piper Sandler analyst Yasmeen Rahimi raised the price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG) to $220.00 (from $190.00) while maintaining an Overweight rating.</p><p>The analyst commented: "We caught up with DRUG following earnings, where mgmt reflected confidence in the progress made across programs this past quarter. Starting with PWS, DRUG shared that PoC Ph2a NOVA has kicked-off recruitment with 2 sites activated (another one to be soon) where recent competitor data may provide tailwinds to support patient recruitment. Regarding BMB-101 development in absence epilepsy and DEE, recognize that regulatory discussions are ongoing where DRUG is preparing for a pre-IND http://www.streetinsider.com/Analyst+Comments/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24220+at+Piper+Sandler/26524539.html Wed, 20 May 2026 06:52:52 -0400 DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26524163.html si-local-file:///var/storage/secattach/20260520/26524163.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26524163.html Wed, 20 May 2026 06:01:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26524163.html si-local-file:///var/storage/secattach/20260520/26524163.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/26524163.html Wed, 20 May 2026 06:01:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507634.html si-local-file:///var/storage/secattach/20260515/26507634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507634.html Fri, 15 May 2026 17:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507634.html si-local-file:///var/storage/secattach/20260515/26507634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507634.html Fri, 15 May 2026 17:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502859.html si-local-file:///var/storage/secattach/20260515/26502859.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502859.html Fri, 15 May 2026 12:37:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502859.html si-local-file:///var/storage/secattach/20260515/26502859.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502859.html Fri, 15 May 2026 12:37:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502861.html si-local-file:///var/storage/secattach/20260515/26502861.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502861.html Fri, 15 May 2026 12:37:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502861.html si-local-file:///var/storage/secattach/20260515/26502861.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502861.html Fri, 15 May 2026 12:37:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vivo+Opportunity+Fund+Holdings%2C+L.P./26480037.html si-local-file:///var/storage/secattach/20260512/26480037.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vivo+Opportunity+Fund+Holdings%2C+L.P./26480037.html Tue, 12 May 2026 21:44:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vivo+Opportunity+Fund+Holdings%2C+L.P./26480037.html si-local-file:///var/storage/secattach/20260512/26480037.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Vivo+Opportunity+Fund+Holdings%2C+L.P./26480037.html Tue, 12 May 2026 21:44:00 -0400 DRUG O.53098441